All In MedTech

Device Trial Radar · NCT03711019

Efficacy of Convulsive Therapies During Continuation

Cognitive Outcomes and the Response/Remission Efficacy of Convulsive Therapies During Continuation: CORRECT-C Trial

Last checked: Nov 19, 2026Latest source record: Nov 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 106 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

106

Actual

Start

Oct 22, 2018

Primary completion

Oct 10, 2024

Study completion Oct 10, 2024

Sponsor

Lead sponsor
Centre for Addiction and Mental HealthAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of British Columbia; Ontario Shores Centre for Mental Health Sciences; Brain Canada
First posted
Oct 18, 2018

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial aims to assess the efficacy and tolerability of Magnetic Seizure Therapy (MST) and two different forms of electroconvulsive therapy (ECT) in sustaining response during and after a course of continuation treatment.

Conditions

  • Depression
  • Bipolar Depression
  • Unipolar Depression
  • Treatment Resistant Depression

Interventions

  • Magnetic Seizure Therapy (MST)Device

    MST treatment will be administered using the MagPro MST with a Cool TwinCoil over the frontal cortex in the midline position using 100 Hz stimulation. Seizure threshold will have been determined during the first treatment session following a standard established protocol in the context of CREST-MST or CORRECT-BD. Treatment in the continuation phase will be administered at the same stimulus dose as the last treatment in acute phase. This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes.

  • RUL-UB ECTDevice

    In the RUL-UB ECT arm treatment, the MECTA spectrum 5000Q or MECTA Sigma machine will be used, which are FDA approved devices used for providing standard-of-care clinical ECT treatments. Seizure threshold will have been determined during the first treatment session following a standard established protocol in the context of CREST-MST or CORRECT-BD. Treatment in the continuation phase will be administered at the same stimulus dose as the last treatment in acute phase. This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes.

  • Bitemporal ECTDevice

    Bitemporal ECT treatments will be administered using the MECTA spECTrum 5000Q or MECTA Sigma, which are FDA approved devices used for providing standard-of-care clinical ECT treatments. Bitemporal ECT will be administered at 1.5 times seizure threshold according to standard clinical practice. Treatment in the continuation phase will be administered at the same stimulus dose as the last treatment in acute phase. This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Difference in HRSD-24 Scores between MST and RUL-UB at 6 monthsTime frame: 6 months
  2. Cognitive adverse effects as indexed by the Autobiographical Memory Test (AMT)Time frame: 6 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • UBC Hospital, University of British Columbia (UBC)

    Vancouver, British Columbia, Canada

  • Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health

    Toronto, Ontario, Canada

  • Ontario Shores Centre for Mental Health Sciences

    Whitby, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.